Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia 48Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Lymphoma 40Myelodysplastic Syndromes 30Lymphoma, Non-Hodgkin 29Lymphoma, Large B-Cell, Diffuse 27Lymphoma, Follicular 27Leukemia, Myeloid, Acute 26Leukemia, Myeloid, Chronic-Phase 25Leukemia, Lymphocytic, Chronic, B-Cell 24Burkitt Lymphoma 24Leukemia, Myeloid, Accelerated Phase 23Lymphoma, Large-Cell, Immunoblastic 22Multiple Myeloma 20Hodgkin Disease 20Myeloproliferative Disorders 19Lymphoma, Mantle-Cell 18Lymphoma, B-Cell, Marginal Zone 18Graft vs Host Disease 18Blast Crisis 18Neoplasms, Plasma Cell 17Leukemia, Myelomonocytic, Chronic 16Dendritic Cell Sarcoma, Interdigitating 15Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 14Congenital Abnormalities 14Recurrence 13Anemia, Refractory, with Excess of Blasts 13Primary Myelofibrosis 12Myelodysplastic-Myeloproliferative Diseases 12Lymphoma, T-Cell, Cutaneous 10

Interventions

Infliximab 3Fecal Microbiota Transplantation 3vedolizumab 2Prednisone 2LDP-02 2Immunoglobulin G 2Disulfides 2CT-P13 2tocilizumab 1prednylidene 1fish oil triglycerides 1deltacortene 1Standard of Care 1Practice Guidelines as Topic 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Loperamide 1Injections 1Endoscopy 1Diagnosis 1Colonoscopy 1Cell- and Tissue-Based Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Colitis × Methylprednisolone × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡